Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | NQO1 | P15559 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595744 | 1.00 | KMT2A (0.55) | KMT2AMEN1NPC1APOBEC3GMAPT | |
| SCHEMBL3786884 | 0.85 | MAPT (0.55) | KMT2AMEN1NPC1MAPTALDH1A1 | |
| SCHEMBL3785877 | 0.85 | DRD4 (0.54) | KMT2ANPC1MAPTTSHRTP53 | |
| SCHEMBL1876235 | 0.84 | KMT2A (0.59) | KMT2AMEN1NPC1APOBEC3GMAPT | |
| SCHEMBL5952240 | 0.81 | MEN1 (0.66) | KMT2AMEN1NPC1APOBEC3GMAPT | |
| SCHEMBL30646246 | 0.81 | MEN1 (0.66) | KMT2AMEN1NPC1APOBEC3GMAPT | |
| SCHEMBL1548013 | 0.81 | KDM4E (0.58) | KMT2AMEN1NPC1APOBEC3GMAPT | |
| SCHEMBL29684116 | 0.79 | DRD4 (0.52) | MAPTALDH1A1LMNATSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL9517722 | 0.79 | MEN1 (0.63) | KMT2AMEN1NPC1APOBEC3GMAPT | |
| Hydrochloric Acid SCHEMBL11702133 | 0.79 | MEN1 (0.63) | KMT2AMEN1NPC1APOBEC3GMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | OPTIKIRA LLC (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4192462-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING SAME | Optikira LLC (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032078-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING SAME | Optikira, LLC (US) | 2022-02-10 | — | — | WO | disclosed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3475276-B1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | US HEALTH (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10836759-B2 | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2020-11-17 | — | — | US | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190241551-A1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2019-08-08 | — | — | US | disclosed |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2019-03-07 | — | — | US | disclosed |
| EP-2217602-B1 | 1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2018-08-29 | — | — | EP | disclosed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | disclosed |
| US-8648085-B2 | 1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-4250090-A | COLORFASTNESS; WETFASTNESS; ACID AZO DYES | BASF AKTIENGESELLSCHAFT (DE) | 1981-02-10 | — | — | US | disclosed |
| US-4079052-A | Diazopigments containing pyridine derivatives | CIBA-GEIGY CORPORATION (US) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836759-B2 | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | IDH1, IDH2, IDH3B | KMT2A 984/4885MEN1 21/4885NPC1 2713/4885 |
| US-20110015193-A1 | 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE1C | KMT2A 1720/4885MEN1 1111/4885NPC1 961/4885 |
| US-20190241551-A1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | IDH1, IDH2, IDH3B | KMT2A 984/4885MEN1 21/4885NPC1 2713/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | KMT2A 1474/4885MEN1 174/4885NPC1 724/4885 |
| US-20230331719-A1 | Pyrazolopyridine Compounds and Methods of Inhibiting IRE1 Using Same | XBP1, ERN1, ERN2 | KMT2A 3798/4885MEN1 3460/4885NPC1 2038/4885 |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | IDH1, IDH3B, IDH3A | KMT2A 221/4885MEN1 81/4885NPC1 3863/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | KMT2A 221/4885MEN1 81/4885NPC1 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.